Lundbeck will present new preclinical findings at the European Epilepsy Congress in Athens this September, showcasing the dual-action mechanism of its investigational drug, bexicaserin. The compound, currently in Phase III trials, is designed to simultaneously inhibit and excite neuronal pathways to address complex epilepsy syndromes.
The research, scheduled for presentation between September 5 and 9, highlights bexicaserin as a highly selective superagonist of the 5-HT2c receptor. By modulating these receptors, the drug aims to restore balance in brain networks prone to hyperexcitability, a common driver of seizures in developmental and epileptic encephalopathies (DEEs).
Tarek Samad, executive vice president of research and development at Lundbeck, emphasized that the data help clarify the scientific rationale behind the drug’s performance in the ongoing global Phase III DEEp program. This program includes the DEEp OCEAN trial for patients with Lennox–Gastaut syndrome and the DEEp SEA trial focused on Dravet syndrome.
Beyond the primary oral presentation, the company will share findings from its PACIFIC trial and interim data from expanded access programs. These studies seek to address the significant unmet needs of patients with rare, treatment-resistant epilepsies, for which no single medication is currently approved across all DEE types. While bexicaserin holds Breakthrough Therapy designation from the FDA and in China, it remains an investigational compound with its safety and efficacy profile still under clinical evaluation.
.jpg-hi-res.jpg)
Comments (0)
No comments yet. Be the first!